VESTAR INCREASES REVENUESVestar Inc. (NASDAQ:VSTR) of San Dimas, Calif., President andChief Executive Officer Roger J. Crossley, said: "We areencouraged by our market penetration in Europe during thequarter. AmBiosome is a demand-pull product sold uponphysician requests. Increasing revenues are indicative ofproduct performance in the marketplace."

First quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $2,246 508 +342Net income (loss) (1,603) (1,696) +5Net income per share (loss) (.25) (.26) +4Outstanding shares 6,666 6,424 +4

ALZA INCREASES REVENUES AND EARNINGS

Alza Corp. (AMEX:AZA) of Palo Alto, Calif., said increases in netincome and revenues for the quarter were due primarily toroyalties received from Pfizer Inc. based upon sales ofProcardia XL in the United States. Prodardia XL, introduced byPfizer in late i989 for the treatment of angina andhypertension, has rapidly gained market share, the companysaid. Both interest expense and interest income increasedduring the quarter as a result of Alza's 7.5 percent zero coupondebenture offering in late 1990 and the investment of the $192million of proceeds.

First quarter ended March 31

(Figures in thousands except per-share data.)

1991 1990 Percent change

Revenues $31,688 24,010 +32Net income (loss) 7,601 5,467 +39Net income per share (loss) .21 .16 +31Outstanding shares 36,777 35,027 +5

(c) 1997 American Health Consultants. All rights reserved.

No Comments